2Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease[J]. Circulation, 1979,59:607-609.
3World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus [ M ].Geneva: World Health Organization, 1999.
4Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisome proliferator-activated receptor-gamma (PPARγ)expression and reduction of MMP-9 activaty through PPARγ activation in monocular phagocytes in vitro [J]. Am J Pathol, 1998,153:17-23.
5Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits [ J ]. Circulation, 2006,113 : 1929-1932.
6Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress[ J].Circ Res,2001,88:1291-1298.
7Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalluproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris[J]. Am J Cardiol ,2006,97:175-180.
8Matsunaga T, Abe N, Kameda K, et al. Circulating level of gelatinase activity prediets ventrieular remodeling in patients with acute myocardial infaretion [ J ]. Int J Cardiol, 2005,105 : 203-208.
9Kalela A, Limnell V, Aittoniemi J, et al. Serum matrix metalloproteinase-9 and venous bypass graft occlusion[J]. Scrand J Clin Lab Invest,2006,66:7-14.
10Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2003,23 : 283-288.
